Table 1.
Therapeutic potential of NAD+ boosters in human
| Human diseases in ICD-11 classification | Conditions | Interventions | NCT Number |
|---|---|---|---|
| Diseases of the circulatory system | Acute coronary syndrome | Niacin | NCT00855257 |
| Aortocoronary saphenous vein Bypass graft atherosclerosis | Niacin | NCT01221402 | |
| Arterial occlusive diseases | Niacin | NCT00000539 | |
| Atherogenic dyslipidemia | Niacin | NCT03615534 | |
| Atherosclerosis | Niacin; NR | NCT00150722; NCT00127218; NCT02812238 | |
| Cardiovascular diseases | Niacin | NCT02322203; NCT00461630; NCT01200160; NCT00000512; NCT00000483; NCT00000482; NCT00000553; NCT00000461; NCT00880178; NCT00246376; NCT01921010 | |
| Carotid atherosclerosis | Niacin | NCT00804843 | |
| Heart failure | Niacin; NR | NCT00458055; NCT00590629; NCT02003638; NCT01178320; NCT00715273; NCT00298909; NCT01126073; NCT03423342; NCT03727646 | |
| Established carotid atherosclerosis | Niacin | NCT00307307 | |
| Intermittent claudication | Niacin | NCT00062556; NCT00071266 | |
| Peripheral artery disease | Niacin; NR | NCT00687076; NCT03743636 | |
| Pregnancy induced hypertension | Nicotinamide | NCT02213094 | |
| Vascular diseases | NR | NCT04040959 | |
| Diseases of the genitourinary system | Acute kidney injury | Niacinamide; NR | NCT02701127; NCT04342975; NCT03176628 |
| Chronic kidney disease | Nicotinamide; Niacin; NR | NCT02258074; NCT01200784; NCT00852969; NCT03579693 | |
| Polycystic kidney disease | Niacinamide | NCT02558595; NCT02140814 | |
| Mental, behavioral or neurodevelopmental disorders | Acute schizophrenia | Niacinamide | NCT00140166 |
| Depressive disorder | Niacin | NCT03866174 | |
| Obsessive-compulsive disorder | Niacin | NCT03356483 | |
| Post traumatic stress disorder | Niacin | NCT03752918 | |
| Schizophrenia | Niacin | NCT02458924 | |
| Aging | Aging | NR; Niacin and Nicotinamide | NCT02921659; NCT03821623; NCT03310034 |
| Diseases of the nervous system | Alzheimer’s disease | Nicotinamide | NCT00580931; NCT03061474 |
| Chemotherapy-induced peripheral neuropathy | NR | NCT04112641; NCT03642990 | |
| Cognitive function | NR | NCT03562468 | |
| Diabetic neuropathy peripheral | NR | NCT03685253 | |
| Ischemic stroke | Niacin | NCT00796887 | |
| Mild cognitive impairment | NR | NCT03482167; NCT02942888 | |
| Multiple sclerosis | Niacinamide | NCT01381354 | |
| Parkinson’s disease | Niacin; NR | NCT03808961; NCT03462680; NCT03816020 | |
| Progressive supranuclear palsy | Niacinamide | NCT00605930 | |
| Retinal vein occlusion | Niacin | NCT00493064 | |
| Others | Bioavailability | NR | NCT02712593 |
| Cystic fibrosis | NR | NCT04166396 | |
| Development | Nicotinamide | NCT03268902 | |
| Flushing | Niacin | NCT00930839; NCT00533611; NCT00536237 | |
| Gulf War illness | Niacin | NCT01672710 | |
| Healthy | Nicotinamide; Niacin; NR | NCT03136705; NCT03974685; NCT01809301; NCT00359281; NCT01258491; NCT00608699; NCT01275300; NCT00953667; NCT03838822; NCT02191462; NCT02678611; NCT03151707; NCT02300740; NCT03818802 | |
| Melasma | Niacinamide | NCT03392623 | |
| Muscle injury | NR | NCT03754842 | |
| Preeclampsia | Nicotinamide | NCT03419364 | |
| Psychosis | Niacin | NCT01720095 | |
| Recovery of function | NR | NCT03635411 | |
| Sickle cell disease | Niacin | NCT00508989 | |
| Sleep apnea | Niacin | NCT04234217 | |
| Inflammation | NR | NCT04110028 | |
| Neoplasms | Bladder cancer | Niacinamide | NCT00033436 |
| Non-melanoma skin cancer | Niacinamide | NCT03769285 | |
| Non-small-cell lung carcinoma | Niacinamide | NCT02416739 | |
| Non-Hodgkin’s lymphoma | Niacin; Niacinamide | NCT00957359; NCT02702492; NCT04281420; NCT00691210 | |
| Cancer | NR | NCT03789175 | |
| Multiple myeloma | Nicotinamide | NCT03019666 | |
| Diseases of the skin | Contact dermatitis of hands | Niacinamide | NCT04218500 |
| Hand-foot skin reaction | Niacin | NCT04242927 | |
| Hyperpigmentation | Niacinamide | NCT01542138 | |
| Psoriasis | Nicotinamide; NR | NCT01763424; NCT04271735 | |
| Endocrine, nutritional or metabolic diseases | Diabetes mellitus type 2 | Niacin | NCT00485758; NCT03685773; NCT00618995; NCT02153879; NCT03867500 |
| Dyslipidemia | Niacin | NCT00903617; NCT00194402; NCT01984073; NCT00944645; NCT00943124; NCT00626392; NCT00111891; NCT00111891; NCT00728910; NCT00961636; NCT01803594; NCT02642159; NCT01104519; NCT01071291; NCT00079638; NCT01250990 | |
| Glucose metabolism disorders | NMN supplement | NCT03151239 | |
| Hypercholesterolemia | Niacin | NCT00376584; NCT02890992; NCT03510884; NCT01321034; NCT00769132; NCT00080275; NCT00082251; NCT00271817; NCT00533312; NCT01054508; NCT03510715; NCT00378833; NCT00652431; NCT00536510 | |
| Hyperlipidemia | Niacin | NCT00244231; NCT00203476; NCT00465088; NCT00345657 | |
| Hyperphosphatemia | Niacinamide | NCT00508885; NCT00316472 | |
| Insulin sensitivity | Niacin | NCT01216956 | |
| Metabolic disturbance | NR | NCT02689882 | |
| Metabolic syndrome | Niacin | NCT00300365; NCT00346970; NCT02061267; NCT00286234; NCT00304993 | |
| Mitochondrial diseases | Niacin,NR | NCT03973203; NCT03432871 | |
| Obesity | Niacin,NR | NCT01083329; NCT02303483; NCT03951285; NCT02835664 | |
| Polycystic ovary syndrome | Niacin | NCT01118598 | |
| Primary hypercholesterolemia | Niacin | NCT00269204; NCT00479388; NCT01012219; NCT00269217 | |
| Undernutrition | Nicotinamide | NCT04012177 | |
| Infection | HIV infections | Niacin,NR | NCT02018965; NCT00986986; NCT00046267; NCT01426438; NCT00202228 |
| Diseases of the digestive system | Non alcoholic fatty liver disease | Niacinamide | NCT03850886; NCT00262964; NCT04330326 |
| Diseases of the blood or blood-forming organs | Sickle cell disease | Nicotinamide | NCT04055818 |